| [1] |
Hou J,Li JY,Qiu LG.Multiple Myeloma Principal and Practice[M].Shanghai: Shanghai Science and Technology Press,2011:35.
[侯健,李建勇,邱录贵.多发性骨髓瘤理论与实践[M].上海：上海科学技术出版社,2011:35.]
|
| [2] |
Sawyer JR,Tricot G,Mattox S,et al. Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin [J]．Blood,1998,91(5):1732-41．
|
| [3] |
Shaughnessy JD Jr, Zhan F, Burington BE, et al．A validated gene expression model of high- risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1[J]. Blood, 2007, 109(6):2276-84.
|
| [4] |
Rajkumar SV, Harousseau JL, Durie B,et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1[J].Blood, 2011,117(18):4691-5.
|
| [5] |
Sawyer JR, Waldron JA, Jagannath S,et al. Cytogeneticfindingsin200patients with multiple myeloma[J]. Cancer Genet Cytogenet,1995,82(1):41-9.
|
| [6] |
Chang H，Ning Y，Qi X，et al．Chromosome lp2l deletion is a novel prognostic marker in patients with multiple myeloma[J]．Br J Haematol,2007,139(1):51-4．
|
| [7] |
Lai YY, Huang XJ, Cai Z, et al．Prognostic power of abnormal cytogenetics for multiple myeloma: a multicenter study in China[J]. Chin Med J(Engl),2012,125(15):2663-70.
|
| [8] |
Hu Y, Chen L, Sun CY,et al. Clinical significance of chromosomal abnormalities detected by interphase fluorescence in situ hybridization in newly diagnosed multiple myeloma patients[J]. Chin Med J(Engl),2011,124(19):2981-5.
|
| [9] |
Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome[J]. Blood, 2007,109(8):3489-95.
|
| [10] |
Boyd KD, Ross FM, Chiecchio L, et al. A novel prognostic model in myeloma based on co- segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial[J]. Leukemia,2012,26(2):349-55.
|
| [11] |
Fonseca R, Van Wier SA, Chng WJ, et al. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma[J].Leukemia,2006, 20(11): 2034-40.
|
| [12] |
Grzasko N, Hus M, Pluta A,et al. Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients[J].Hematol Oncol,2012, 31(1):41-8.
|
| [13] |
Jagannath S, Richardson PG, Sonneveld P, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials[J]. Leukemia, 2007,21(1):151-7.
|
| [14] |
San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma[J]. N Engl J Med, 2008,359(9):906-17.
|
| [15] |
Inoue J, Otsuki T, Hirasawa A, et al．Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug- resistance phenotype in multiple myeloma[J]. Am J Pathol,2004,165(1):71-81.
|
| [16] |
Ganoth D, Bornstein G, Ko TK, et al. The cell-cycle regulatory protein Cks1 is required for SCF(Skp2)-mediated ubiquitinylation of p27[J]. Nat Cell Biol,2001,3(3)：321-4.
|
下载:
